StockWatch
·
Biotechnology: Pharmaceutical Preparations
Corporate GovernanceJul 29, 2026, 04:08 PM

Longeveron Reconstitutes Audit Committee for Nasdaq Compliance

AI Summary

Longeveron Inc. announced the reconstitution of its Audit Committee to regain compliance with Nasdaq Listing Rule 5605(c)(2)(A). Following a temporary period of non-compliance due to a board resignation, the company's Board of Directors approved the new committee composition on July 24, 2026. The new committee includes Dr. Deborah Ascheim, Ms. Leah Rush Cann, Dr. George Paletta, and Ms. Ursula Ungaro, with all members qualifying as independent and Ms. Cann as an audit committee financial expert.

Key Highlights

  • Company previously failed to comply with Nasdaq Listing Rule 5605(c)(2)(A).
  • Rule requires at least three independent directors and one financial expert on audit committee.
  • Board approved reconstitution of Audit Committee on July 24, 2026.
  • New Audit Committee members: Dr. Ascheim, Ms. Cann, Dr. Paletta, Ms. Ungaro.
  • All new Audit Committee members qualify as independent.
  • Ms. Leah Rush Cann qualifies as an audit committee financial expert.